Matches in Wikidata for { <http://www.wikidata.org/entity/Q90956347> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q90956347 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90956347 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90956347 description "scientific article published on 14 October 2019" @default.
- Q90956347 description "wetenschappelijk artikel" @default.
- Q90956347 description "наукова стаття, опублікована 14 жовтня 2019" @default.
- Q90956347 name "Neuromyelitis optica spectrum disorder after treatment with pembrolizumab" @default.
- Q90956347 name "Neuromyelitis optica spectrum disorder after treatment with pembrolizumab" @default.
- Q90956347 type Item @default.
- Q90956347 label "Neuromyelitis optica spectrum disorder after treatment with pembrolizumab" @default.
- Q90956347 label "Neuromyelitis optica spectrum disorder after treatment with pembrolizumab" @default.
- Q90956347 prefLabel "Neuromyelitis optica spectrum disorder after treatment with pembrolizumab" @default.
- Q90956347 prefLabel "Neuromyelitis optica spectrum disorder after treatment with pembrolizumab" @default.
- Q90956347 P1433 Q90956347-74CD2063-CEDC-44B7-9C0F-170B5B762E91 @default.
- Q90956347 P1476 Q90956347-4168A152-0214-4920-93BD-F495A4266989 @default.
- Q90956347 P2093 Q90956347-2500C099-3AA2-4B1B-9F96-F1184CDFF071 @default.
- Q90956347 P2093 Q90956347-2CF8D03B-4FAA-4C04-9CB3-38D56DE7063B @default.
- Q90956347 P2093 Q90956347-3E7F6993-A2A3-4AAD-ADC3-5D6DCFEAE9A6 @default.
- Q90956347 P2093 Q90956347-50890F53-A922-4CD7-AA47-027C2397C551 @default.
- Q90956347 P2093 Q90956347-554FC798-55EA-44B1-983D-7F0AEFD9FD92 @default.
- Q90956347 P2093 Q90956347-564CE956-63D0-4272-8042-637A10999D85 @default.
- Q90956347 P2093 Q90956347-5A56375F-48A3-4CE3-9EBB-AF43EFEB3566 @default.
- Q90956347 P304 Q90956347-A27A4CD6-A87C-4B7F-969B-ABE1C60D561E @default.
- Q90956347 P31 Q90956347-40437979-5460-41FD-916E-67B13FE36DA8 @default.
- Q90956347 P356 Q90956347-92D5C482-28DD-463B-9790-7CC06B5BB31C @default.
- Q90956347 P478 Q90956347-C00D47A2-0A05-4F65-91B5-55E46DE60DB9 @default.
- Q90956347 P577 Q90956347-7C6CD6AF-8755-4731-974A-776CC4EEAE27 @default.
- Q90956347 P698 Q90956347-4603A37B-ADB9-430F-8A11-F8B2E387B766 @default.
- Q90956347 P921 Q90956347-1FFD4D8B-B917-4C07-9433-8200562EB7F9 @default.
- Q90956347 P921 Q90956347-AE6F5B55-3617-4731-9943-78301822D190 @default.
- Q90956347 P356 J.MSARD.2019.101447 @default.
- Q90956347 P698 31655267 @default.
- Q90956347 P1433 Q26842267 @default.
- Q90956347 P1476 "Neuromyelitis optica spectrum disorder after treatment with pembrolizumab" @default.
- Q90956347 P2093 "Anri Hattori" @default.
- Q90956347 P2093 "Emi Nakagawa" @default.
- Q90956347 P2093 "Kazumasa Yokoyama" @default.
- Q90956347 P2093 "Nobutaka Hattori" @default.
- Q90956347 P2093 "Taiji Tsunemi" @default.
- Q90956347 P2093 "Tomoyo Shimada" @default.
- Q90956347 P2093 "Yasunobu Hoshino" @default.
- Q90956347 P304 "101447" @default.
- Q90956347 P31 Q13442814 @default.
- Q90956347 P356 "10.1016/J.MSARD.2019.101447" @default.
- Q90956347 P478 "37" @default.
- Q90956347 P577 "2019-10-14T00:00:00Z" @default.
- Q90956347 P698 "31655267" @default.
- Q90956347 P921 Q13896859 @default.
- Q90956347 P921 Q611458 @default.